A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer

Cited by papers we hold 11

• Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside · 2024
  No notice
• Harnessing anti‐tumor and tumor‐tropism functions of macrophages via nanotechnology for tumor immunotherapy · 2022
  No notice
• Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy · 2022
  No notice
• Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets · 2022
  No notice
• Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting · 2021
  No notice
• Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy · 2021
  No notice
• Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review · 2021
  No notice
• The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects · 2020
  No notice
• Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy · 2019
  No notice
• Macrophages and hepatocellular carcinoma · 2019
  No notice
• Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.